117 related articles for article (PubMed ID: 17279417)
21. TGF-beta promotes the establishment of renal cell carcinoma bone metastasis.
Kominsky SL; Doucet M; Brady K; Weber KL
J Bone Miner Res; 2007 Jan; 22(1):37-44. PubMed ID: 17032147
[TBL] [Abstract][Full Text] [Related]
22. TGFBI-promoted adhesion, migration and invasion of human renal cell carcinoma depends on inactivation of von Hippel-Lindau tumor suppressor.
Shang D; Liu Y; Yang P; Chen Y; Tian Y
Urology; 2012 Apr; 79(4):966.e1-7. PubMed ID: 22341602
[TBL] [Abstract][Full Text] [Related]
23. TGF-beta inhibits IL-2-induced tyrosine phosphorylation and activation of Jak-1 and Stat 5 in T lymphocytes.
Bright JJ; Kerr LD; Sriram S
J Immunol; 1997 Jul; 159(1):175-83. PubMed ID: 9200453
[TBL] [Abstract][Full Text] [Related]
24. Immunotherapy for human renal cell carcinoma by adoptive transfer of autologous transforming growth factor beta-insensitive CD8+ T cells.
Wang L; Wen W; Yuan J; Helfand B; Li Y; Shi C; Tian F; Zheng J; Wang F; Chen L; Liang L; Zhou L; Lee C; Chen Z; Guo Y; Wang H; Zhang Q; Qin W
Clin Cancer Res; 2010 Jan; 16(1):164-73. PubMed ID: 20028741
[TBL] [Abstract][Full Text] [Related]
25. TGF-beta 1 induces proliferation in human renal fibroblasts via induction of basic fibroblast growth factor (FGF-2).
Strutz F; Zeisberg M; Renziehausen A; Raschke B; Becker V; van Kooten C; Müller G
Kidney Int; 2001 Feb; 59(2):579-92. PubMed ID: 11168939
[TBL] [Abstract][Full Text] [Related]
26. RAGE- and TGF-beta receptor-mediated signals converge on STAT5 and p21waf to control cell-cycle progression of mesangial cells: a possible role in the development and progression of diabetic nephropathy.
Brizzi MF; Dentelli P; Rosso A; Calvi C; Gambino R; Cassader M; Salvidio G; Deferrari G; Camussi G; Pegoraro L; Pagano G; Cavallo-Perin P
FASEB J; 2004 Aug; 18(11):1249-51. PubMed ID: 15180953
[TBL] [Abstract][Full Text] [Related]
27. Radiosensitization by inhibiting STAT1 in renal cell carcinoma.
Hui Z; Tretiakova M; Zhang Z; Li Y; Wang X; Zhu JX; Gao Y; Mai W; Furge K; Qian CN; Amato R; Butler EB; Teh BT; Teh BS
Int J Radiat Oncol Biol Phys; 2009 Jan; 73(1):288-95. PubMed ID: 19100922
[TBL] [Abstract][Full Text] [Related]
28. Molecular role of TGF-beta, secreted from a new type of CD4+ suppressor T cell, NY4.2, in the prevention of autoimmune IDDM in NOD mice.
Han HS; Jun HS; Utsugi T; Yoon JW
J Autoimmun; 1997 Jun; 10(3):299-307. PubMed ID: 9218758
[TBL] [Abstract][Full Text] [Related]
29. Decreased expression of bone morphogenetic protein (BMP) receptor type II correlates with insensitivity to BMP-6 in human renal cell carcinoma cells.
Kim IY; Lee DH; Lee DK; Kim BC; Kim HT; Leach FS; Linehan WM; Morton RA; Kim SJ
Clin Cancer Res; 2003 Dec; 9(16 Pt 1):6046-51. PubMed ID: 14676131
[TBL] [Abstract][Full Text] [Related]
30. JAK3/STAT5/6 pathway alterations are associated with immune deviation in CD8 T cells in renal cell carcinoma patients.
Cavalcanti E; Gigante M; Mancini V; Battaglia M; Ditonno P; Capobianco C; Cincione RI; Selvaggi FP; Herr W; Storkus WJ; Gesualdo L; Ranieri E
J Biomed Biotechnol; 2010; 2010():935764. PubMed ID: 20339477
[TBL] [Abstract][Full Text] [Related]
31. Renal cell carcinomas produce IL-6, IL-10, IL-11, and TGF-beta 1 in primary cultures and modulate T lymphocyte blast transformation.
Knoefel B; Nuske K; Steiner T; Junker K; Kosmehl H; Rebstock K; Reinhold D; Junker U
J Interferon Cytokine Res; 1997 Feb; 17(2):95-102. PubMed ID: 9058315
[TBL] [Abstract][Full Text] [Related]
32. Transforming growth factor beta1 is a target for the von Hippel-Lindau tumor suppressor and a critical growth factor for clear cell renal carcinoma.
Ananth S; Knebelmann B; Grüning W; Dhanabal M; Walz G; Stillman IE; Sukhatme VP
Cancer Res; 1999 May; 59(9):2210-6. PubMed ID: 10232610
[TBL] [Abstract][Full Text] [Related]
33. Reciprocal roles of STAT3 and STAT5 in nasal polyposis.
Wang XQ; Hu GH; Kou W; Shen Y; Kang HY; Hong SL
Am J Otolaryngol; 2012; 33(6):741-52. PubMed ID: 22959364
[TBL] [Abstract][Full Text] [Related]
34. Pharmacodynamic analysis of tofacitinib and basiliximab in kidney allograft recipients.
Vafadari R; Quaedackers ME; Kho MM; Mol WM; Chan G; Weimar W; Baan CC
Transplantation; 2012 Sep; 94(5):465-72. PubMed ID: 22960764
[TBL] [Abstract][Full Text] [Related]
35. Effects of TGF-β signaling in clear cell renal cell carcinoma cells.
Boström AK; Lindgren D; Johansson ME; Axelson H
Biochem Biophys Res Commun; 2013 May; 435(1):126-33. PubMed ID: 23618868
[TBL] [Abstract][Full Text] [Related]
36. Transforming growth factor-beta1 and renal cell cancer: cell growth, mRNA expression and protein production of cytokines.
Shimabukuro T; Ohmoto Y; Naito K
J Urol; 2003 May; 169(5):1865-9. PubMed ID: 12686863
[TBL] [Abstract][Full Text] [Related]
37. The transforming growth factor-beta/SMAD signaling pathway is present and functional in human mesangial cells.
Poncelet AC; de Caestecker MP; Schnaper HW
Kidney Int; 1999 Oct; 56(4):1354-65. PubMed ID: 10504488
[TBL] [Abstract][Full Text] [Related]
38. Altered messenger RNA and protein expressions for insulin-like growth factor family members in clear cell and papillary renal cell carcinomas.
Cheung C; Vesey D; Cotterill A; Douglas M; Gobe G; Nicol D; Johnson D
Int J Urol; 2005 Jan; 12(1):17-28. PubMed ID: 15661050
[TBL] [Abstract][Full Text] [Related]
39. Cytoplasmic Accumulation of Heterogeneous Nuclear Ribonucleoprotein K Strongly Promotes Tumor Invasion in Renal Cell Carcinoma Cells.
Otoshi T; Tanaka T; Morimoto K; Nakatani T
PLoS One; 2015; 10(12):e0145769. PubMed ID: 26713736
[TBL] [Abstract][Full Text] [Related]
40. Regulatory T cells and TGF-β1 in clinically localized renal cell carcinoma: Comparison with age-matched healthy controls.
Kim CS; Kim Y; Kwon T; Yoon JH; Kim KH; You D; Hong JH; Ahn H; Jeong IG
Urol Oncol; 2015 Mar; 33(3):113.e19-25. PubMed ID: 25499257
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
